- Home
- RENB vs XBIT Comparison
RENB vs XBIT Comparison
Compare RENB & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- XBIT
- Stock Information
- Founded
- RENB 2011
- XBIT 2005
- Country
- RENB United States
- XBIT United States
- Employees
- RENB N/A
- XBIT N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- XBIT Pharmaceuticals and Biotechnology
- Sector
- RENB Health Care
- XBIT Health Care
- Exchange
- RENB Nasdaq
- XBIT Nasdaq
- Market Cap
- RENB 121.3M
- XBIT 105.2M
- IPO Year
- RENB N/A
- XBIT 2015
- Fundamental
- Price
- RENB $0.35
- XBIT $2.94
- Analyst Decision
- RENB
- XBIT
- Analyst Count
- RENB 0
- XBIT 0
- Target Price
- RENB N/A
- XBIT N/A
- AVG Volume (30 Days)
- RENB 855.6K
- XBIT 55.6K
- Earning Date
- RENB 05-14-2025
- XBIT 05-09-2025
- Dividend Yield
- RENB N/A
- XBIT N/A
- EPS Growth
- RENB N/A
- XBIT N/A
- EPS
- RENB N/A
- XBIT N/A
- Revenue
- RENB N/A
- XBIT N/A
- Revenue This Year
- RENB N/A
- XBIT N/A
- Revenue Next Year
- RENB N/A
- XBIT N/A
- P/E Ratio
- RENB N/A
- XBIT N/A
- Revenue Growth
- RENB N/A
- XBIT N/A
- 52 Week Low
- RENB $0.32
- XBIT $2.65
- 52 Week High
- RENB $2.70
- XBIT $9.45
- Technical
- Relative Strength Index (RSI)
- RENB 29.29
- XBIT 44.32
- Support Level
- RENB $0.35
- XBIT $2.77
- Resistance Level
- RENB $0.39
- XBIT $3.38
- Average True Range (ATR)
- RENB 0.07
- XBIT 0.33
- MACD
- RENB -0.00
- XBIT -0.01
- Stochastic Oscillator
- RENB 11.00
- XBIT 29.90
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.